Dr. Baz on Varying Treatment Approaches for Patients With Multiple Myeloma

Rachid Baz, MD
Published: Thursday, May 25, 2017



Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.

Historically, physicians tried to avoid alkylating agents for patients who were eligible for transplant, Baz explains. Now, when considering treatments for elderly patients, the determinant outcome of these patients turns out to be based on fitness or frailty. For patients considered to be frail, a doublet regimen of lenalidomide (Revlimid)/dexamethasone that is dose-adjusted, or a subcutaneous injection of weekly bortezomib (Velcade) and dexamethasone could be choices.

For patients of intermediate fitness, a reasonable treatment would be bortezomib, lenalidomide, and dexamethasone. Emerging, ongoing clinical trials are challenging that data for the future.
 
SELECTED
LANGUAGE


Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.

Historically, physicians tried to avoid alkylating agents for patients who were eligible for transplant, Baz explains. Now, when considering treatments for elderly patients, the determinant outcome of these patients turns out to be based on fitness or frailty. For patients considered to be frail, a doublet regimen of lenalidomide (Revlimid)/dexamethasone that is dose-adjusted, or a subcutaneous injection of weekly bortezomib (Velcade) and dexamethasone could be choices.

For patients of intermediate fitness, a reasonable treatment would be bortezomib, lenalidomide, and dexamethasone. Emerging, ongoing clinical trials are challenging that data for the future.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x